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Abstract
Background: RNA interference (RNAi) can potently reduce target gene expression in mammalian
cells and is in wide use for loss-of-function studies. Several recent reports have demonstrated that
short double-stranded RNAs (dsRNAs), used to mediate RNAi, can also induce an interferon-
based response resulting in changes in the expression of many interferon-responsive genes. Off-
target gene silencing has also been described, bringing into question the validity of certain RNAi-
based approaches for studying gene function. We have targeted the plasminogen activator
inhibitor-2 (PAI-2 or SERPINB2) mRNA using lentiviral vectors for delivery of U6 promoter-driven
PAI-2-targeted short hairpin RNA (shRNA) expression. PAI-2 is reported to have anti-apoptotic
activity, thus reduction of endogenous expression may be expected to make cells more sensitive
to programmed cell death.
Results: As expected, we encountered a cytotoxic phenotype when targeting the PAI-2 mRNA
with vector-derived shRNA. However, this predicted phenotype was a potent non-specific effect
of shRNA expression, as functional overexpression of the target protein failed to rescue the
phenotype. By decreasing the shRNA length or modifying its sequence we maintained PAI-2
silencing and reduced, but did not eliminate, cytotoxicity. ShRNA of 21 complementary nucleotides
(21 mers) or more increased expression of the oligoadenylate synthase-1 (OAS1) interferon-
responsive gene. 19 mer shRNA had no effect on OAS1 expression but long-term selective
pressure on cell growth was observed. By lowering lentiviral vector titre we were able to reduce
both expression of shRNA and induction of OAS1, without a major impact on the efficacy of gene
silencing.
Conclusions: Our data demonstrate a rapid cytotoxic effect of shRNAs expressed in human
tumor cell lines. There appears to be a cut-off of 21 complementary nucleotides below which there
is no interferon response while target gene silencing is maintained. Cytotoxicity or OAS1 induction
could be reduced by changing shRNA sequence or vector titre, but stable gene silencing could not
be maintained in extended cell culture despite persistent marker gene expression from the RNAi-
inducing transgene cassette. These results underscore the necessity of careful controls for
immediate and long-term RNAi use in mammalian cell systems.
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Background
Gene silencing is a powerful tool with which to study pro-
tein function. Gene inactivations in mice have revolution-
ised the way we study both basic biology and a plethora
of disease types [1,2]. Gene silencing in human cells has,
until recently, proven difficult to achieve [3]. Research
with plants, flies and worms recently uncovered a mecha-
nism by which eukaryotic cells target mRNAs, and per-
haps even genetic loci, for specific gene silencing. This
process is termed RNA interference (RNAi). RNAi can also
be induced in mammalian cells using double-stranded
RNAs (dsRNAs), and has become the method of choice
for targeted knock-down of gene expression in mamma-
lian cells [4]. The apparent specificity of RNAi also enables
allele-specific gene targeting [5]. Initial studies using RNAi
in mammalian cells centred around transient knock-
down of target gene expression, either using direct trans-
fection of synthetic short interfering RNA (siRNA) [6],
transfection of in vitro transcribed siRNA [7] or transient
expression of short dsRNA via transfection of plasmid
DNA bearing RNA Polymerase III promoter-driven
expression cassettes [8,9]. Short dsRNAs of 19 to 29 base-
paired nucleotides, complementary to the target mRNA,
were expressed as 2 complementary RNAs or as a hairpin
structure (shRNA), and resulted in knock-down of the tar-
get message. While these initial RNAi methods gave a
rapid phenotypic read-out in vitro, stable knock-down of
gene expression is required for monitoring long-term
effects on cell function, for example, in developing tumors
in vivo or in cell-based gene therapy approaches. Efficient
delivery of RNAi-inducing dsRNA or expression cassettes
is required for effective transient and long-term studies.
Transfer of functional shRNAs using lentiviral vectors
appears to be a valid approach for effective, stable con-
struct delivery to both cell lines [10] and primary cells [11-
13]. More recently, using several different expression sys-
tems and target cells, reports have highlighted the utility
and specificity of the RNAi approach [14-17].
Maintaining RNAi-inducing dsRNA below 30 nucleotides
in length was thought to avoid activation of the inter-
feron-induced anti-viral response. PKR is a key anti-viral
regulator and its expression can be induced by the inter-
feron response [18]. PKR is activated when bound to
dsRNA longer than 30 nucleotides, despite interacting
with shorter dsRNA molecules [19]. Four recent reports
have pointed towards limitations to using RNAi as a tool
in mammalian cells. The first demonstrated off-target
gene silencing [20], highlighting the redundancy of short
nucleotide sequences in the human transcriptome. The
second characterised the expression profile of genes as a
result of lentiviral vector-mediated RNAi. Interferon regu-
lated gene expression was increased even with dsRNAs as
short as 19 nucleotides [21]. The third report demon-
strated similar interferon response gene up-regulation,
after transfection of cell lines with synthetic siRNAs as
short as 21 nucleotides [22]. Finally, Scacheri et al docu-
mented significant siRNA sequence-dependent changes in
the expression of non-targeted proteins [23].
In this work we used a simple approach for gene silencing
in human tumor cell lines, using lentiviral vectors for sta-
ble delivery of shRNAs. We aimed to study the effects of
targeting the plasminogen activator inhibitor-2 (PAI-2 or
SERPINB2) mRNA on cell survival in the presence of pro-
apoptotic stimuli. In addition to its inhibitory activity on
the urokinase plasminogen activator, PAI-2 is thought to
have anti-apoptotic properties [24,25]. Its molecular tar-
gets in this respect are unknown. A recent report demon-
strated a functional interaction between PAI-2 and the
retinoblastoma protein cell cycle regulator [26].
Using lentiviral vectors for delivery of RNAi-inducing
expression cassettes we achieved potent PAI-2 gene silenc-
ing, accompanied by a rapid cytotoxic effect. The degree of
cytotoxicity was proportional to shRNA length and induc-
tion of an interferon response gene could be detected
when shRNA of 21 complementary base pairs or more
was expressed. The phenotype was not target gene specific,
as PAI-2 overexpression failed to rescue cytotoxicity and
control hairpins were also cytotoxic. Using lower vector
titre, reduced shRNA expression and interferon response
induction was measured without compromising gene
silencing. Using a 19 complementary base pair shRNA
expression vector, which reduced PAI-2 expression and
induced no initial cytotoxicity or interferon response,
transduced cell marker gene expression was maintained
but gene silencing lost in long-term cell culture. Our
results highlight the need for careful controls to monitor
specificity and maintenance of gene silencing when using
RNAi for stable loss-of-function studies in mammalian
cells.
Results
Efficient transfer of RNAi-inducing cassettes using 
lentiviral vectors
Lentiviral vectors were generated which deliver an expres-
sion cassette for human U6 promoter-driven expression
of short hairpin RNA (shRNA), with exact homology to
the human PAI-2 mRNA. The vector expression cassette
also bears the enhanced green fluorescent protein (GFP)
gene under the control of the EF-1α promoter, and an
internal ribosome entry site (IRES) sequence (see Figure
1A). This cassette allows permanent expression of GFP in
transduced cells, and the possibility of concomitant over-
expression of a further cDNA, between the EF-1α pro-
moter and IRES sequences, not used here. The shRNA
sequences were chosen from the PAI-2 mRNA to include
a 5' guanosine at the U6 promoter transcriptional start
site, to exclude the 5' and 3' 100 nucleotides of the PAI-2BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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Effective gene silencing using lentiviral vectors for RNAi Figure 1
Effective gene silencing using lentiviral vectors for RNAi. The gene transfer cassette common to each vector for RNAi 
is shown in A. Each construction for RNAi was designed for expression of a shRNA, homologous to the target mRNA or with 
a scrambled sequence, driven by the RNA polymerase III-controlled human U6 promoter and ending with a terminator (T) 
sequence. The shRNA is represented by two arrows which encode 19 to 25 nucleotide complementary sequences and are 
joined by an eight nucleotide loop (L). EGFP expression is via the EF-1α promoter, oriented in the opposite direction, driving 
an IRES sequence and the EGFP gene. Each cassette is flanked by the HIV long terminal repeats (LTR), of which the 3' LTR is 
modified to ensure that the vectors are self-inactivating upon integration (SIN). B shows flow cytometry analysis of non-trans-
duced IS-1 cells and cells four days after transduction with the U6PT control vector, a vector for expression of shRNA com-
plementary to a region of the PAI-2 mRNA (sh325) and a vector for expression of a shRNA with a scrambled sh325 sequence 
(sh325scr). C shows an immunoblot for detection of PAI-2 in the cell lysate of these cells. NS highlights a single non-specific 
band which is consistently detected in PAI-2 immunoblots using IS-1 cell lysates. In D, PAI-2 mRNA levels from the same sam-
ples are measured by QRT-PCR of cDNA, using the ∆CT method and hypoxanthine phosphoribosyl transferase (HPRT) as the 
control gene. Each target gene was detected in duplicate, error bars represent the standard deviation of mean values.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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open reading frame, and to be between 30 and 70 % gua-
nosine/cytidine rich. As controls, we have used a vector
leading to expression of GFP alone (EGFP), a vector with
the U6 promoter and transcriptional termination signals
but lacking a hairpin encoding sequence (U6PT), and vec-
tors leading to expression of scrambled sequences of cer-
tain hairpins. Figure 1 demonstrates the efficient
transduction of Isreco-1 (IS-1) human colorectal carci-
noma cells with one such PAI-2 targeting vector (sh325).
Sh325 is designed for expression of a shRNA with a 25
nucleotide double-stranded stretch (a 25 mer) to target
the PAI-2 mRNA. As controls, we used U6PT and a scram-
bled sequence (sh325scr) vector. Four days after transduc-
tion, each cell population expressed high levels of GFP, as
a marker for transduction (Figure 1B). Compared to non-
transduced cells, or cells transduced with the U6PT con-
trol vector, we measured a clear knock-down of endog-
enous PAI-2 protein and mRNA in cells transduced with
the sh325 vector (see figure 1C and 1D).
However, the control vector with a scrambled sequence
(sh325scr) also reduced PAI-2 mRNA and protein levels.
Equal sample loading for immunoblots was confirmed by
Ponceau S staining of nitrocellulose membranes (data not
shown) and the presence of equal amounts of a PAI-2
monoclonal antibody-reactive non-specific band in each
blot (NS in Figure 1C).
Rapid cytotoxic effect of RNAi vectors
Many of the initial loss-of-function studies using RNAi
have measured the phenotypic effect of gene silencing in
the immediate time frame after introduction of the siRNA
or RNAi-inducing expression vector. As seen in Figure 1,
four days after transduction with our vectors appears to be
sufficient for efficient target gene silencing. Transduction
with lentiviral vectors leads to stable long-term integra-
tion of the desired transgene cassette, a key advantage in
their use compared to other transient or less stable expres-
sion systems. Thus we reasoned that transduction with
RNAi-inducing cassettes, using lentiviral vectors, would
also be stable unless the reduction in target gene expres-
sion gave transduced cells a significant growth disadvan-
tage or cytotoxic phenotype. Four to five days after
transduction, IS-1 cells bearing the sh325 construct or
cells transduced with a scrambled sh325 sequence rapidly
changed morphology, compared to U6PT-transduced
control cells. Sh325-transduced cells began to disintegrate
into small particles and detach from cell culture dishes.
After 10 days most of the sh325-transduced cells were
dead while the U6PT-transduced cells were growing like
the parent cell line. The scrambled hairpin vector-trans-
duced cells gave a weaker cytotoxic phenotype, with dete-
riorating cell morphology and some detachment of
transduced cells. Figure 2A shows the morphology of IS-1
cells 6 days after transduction. To understand further this
cytotoxic effect, we performed quantitative RT-PCR (QRT-
PCR) on RNA isolated from IS-1 cells, 4 days after trans-
duction with the same vectors, in order to measure the lev-
els of the 2'5'-oligoadenylate synthetase-1 (OAS1) mRNA
after transduction with each vector. The OAS1 gene is rec-
ognised as an interferon response gene and has also been
monitored elsewhere when using RNAi [21]. We meas-
ured increases in OAS1 expression in both sh325 and
scrambled sh325 vector-transduced cells, whereas con-
trol-transduced cells (U6PT) had equal OAS1 levels to
non-transduced cells (see Figure 2B).
19 mer shRNAs induce less cytotoxicity than longer 
hairpins and do not increase OAS1 expression
As both the target gene-specific and the scrambled
sequence 25 mer shRNAs, sh325 and sh325scr, induced
the OAS1 interferon response gene, we generated further
vectors for delivery of shRNAs with reduced hairpin
length. We reduced the length of sh325, from 25 to 23, 21
and 19 nucleotides and named the novel vectors sh323,
sh321 and sh319, respectively. The truncations were
made at the 3' end of the 25 nucleotide sense strand and
therefore the 5' of its complementary anti-sense sequence
(see Table 1). Each vector was used to transduce IS-1 cells
and the growth of GFP positive cells monitored at 4 and
10 days after transduction, compared to U6PT control-
transduced cells (see Figure 3A). Targeting of the PAI-2
mRNA and protein was monitored, four days after trans-
duction, by QRT-PCR and immunoblotting of cell lysates
(Figure 3B and 3C). While each PAI-2 targeted vector suc-
cessfully reduced PAI-2 mRNA and protein four days after
transduction, a strong negative selection was seen for
shRNA-expressing cells after a further six days of culture.
This selective pressure on transduced cells was stronger
with the 21 mer, 23 mer and 25 mer shRNAs than with the
shorter sh319-derived 19 mer (Figure 3A). OAS1 mRNA
levels were measured by QRT-PCR of transduced cell
cDNA four days after transduction (Figure 3B). The cells
transduced with the 21 mer, 23 mer and 25 mer shRNAs
showed induction of OAS1 mRNA, however, contrary to
our expectations, highest OAS1 levels were obtained with
the 21 mer shRNA. Loss of GFP positive cells over time
was comparable for 21 mer, 23 mer and 25 mer hairpin
constructs.
To determine whether the lack of OAS1 induction was
specific to sh319 or common to other 19 mer shRNAs, fur-
ther transductions and QRT-PCR analysis were performed
on mRNA from IS-1 cells transduced with sh319, sh321
and sh319scr vectors. sh319scr encodes a shRNA with a
scrambled sh319 sequence. This analysis also confirms
the specificity of the PAI-2 silencing, by comparing sh319
to sh319scr. Figure 3D shows that no induction of OAS1
was measured using sh319 or sh319scr vectors and
sh319scr had no effect on the PAI-2 mRNA level.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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Cytotoxicity and OAS1 induction with RNAi vectors Figure 2
Cytotoxicity and OAS1 induction with RNAi vectors. In A, morphology was observed using phase contrast microscopy 
of non-transduced IS-1 cells, or cells six days after transduction with vectors leading to expression of no shRNA (U6PT), a 25 
mer shRNA targeting PAI-2 (sh325) and a scrambled 25 mer control shRNA (sh325scr). B shows comparison of OAS1 expres-
sion in non-transduced cells or cells four days after transduction with U6PT, sh325 and sh325scr vectors, by QRT-PCR. Each 
target gene was detected in duplicate, error bars represent the standard deviation of mean values.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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Cytotoxicity is not target gene specific
To determine if all or part of the cytotoxic effect seen with
our shRNAs was due to down-regulation of PAI-2, we gen-
erated an IS-1 cell line which overexpresses functional
PAI-2. A lentiviral vector was produced which delivers the
wild type PAI-2 cDNA, and used to transduce IS-1 cells.
This resulted in a homogeneous population of cells which
overexpress PAI-2 (see Figure 4A, IS-1 PAI-2 cells). Using
immunoblotting of PAI-2/u-PA complexes, formed by
mixing IS-1 PAI-2 cell lysates with low molecular weight
u-PA, we demonstrated that this overexpressed protein
was functional (see Figure 4B). We transduced these cells
with the series of shRNA-delivering vectors described in
Figure 3 (sh325, sh323, sh321 and sh319), to test whether
functional PAI-2 overexpression could reverse the cyto-
toxic phenotype. As even endogenous PAI-2 is not com-
pletely silenced using these vectors we reasoned that the
RNAi they deliver would not be capable of functionally
silencing overexpressed PAI-2. As predicted, our PAI-2 tar-
geting shRNAs were unable to completely reduce the over-
expressed PAI-2 protein levels (see Figure 4C, compared
to the relative non-specific band intensity in Figure 3C).
However, the cytotoxic effect seen with the parent IS-1 cell
line was also clearly apparent in the PAI-2 overexpressing
cells. We monitored the loss of GFP positive cells in the
transduced PAI-2 overexpressing cell populations and saw
almost identical kinetics, compared to the parent cell line
(compare Figure 3A and Figure 4D). These data show that
the cytotoxic effect is not target gene specific. We also
measured the level of PAI-2 mRNA in this experiment, by
QRT-PCR. Despite a several-fold decrease in overex-
pressed PAI-2 protein level (see immunoblot in Figure
4C) we were unable to detect knock-down of the overex-
pressed mRNA (Figure 4E). In a similar manner to the IS-
1 parent cell line, transduction of PAI-2 overexpressing
cells with sh325, sh323, sh321, but not the sh319 vector,
induced the OAS1 interferon response gene (Figure 4F).
To exclude IS-1 cell-specific effects of our vectors we trans-
duced IS-1 cells and HeLa cells with a GFP control, the
sh319 and the sh319 scrambled sequence (sh319scr) vec-
tors. We monitored the percentage of GFP positive cells at
day 4, 8 and 11 after transduction and observed similar
selective loss of GFP positive cells for the sh319 and
sh319scr vectors, in both cell lines (Table 2).
Reducing lentiviral vector titre can reduce shRNA 
expression level and OAS1 induction, while maintaining 
gene silencing
To understand whether lentiviral vector titre and resulting
shRNA expression levels influence the non-specific effects
described, IS-1 cells were transduced with the U6PT,
sh319 and sh321 vectors as described above and also
using a 10-fold reduction in vector titre (vector titre details
are given in the figure 5 legend). Both sh319 and sh321
vectors effectively down-regulate PAI-2, but only the
sh321 vector induces OAS1 expression (see Figure 3B).
Using 10-fold lower vector titre had little impact on PAI-2
mRNA silencing, as seen using QRT-PCR (Figure 5A), and
resulted in a small decrease in OAS1 mRNA induction
(Figure 5B) in sh321-transduced cells. To assess whether
lower vector titre resulted in lower shRNA expression,
total RNA from cells transduced with different titres of
sh321 vector was subjected to RNase digestion after
hybridization with a 32-P labelled RNA probe, designed to
protect the first 19 nucleotides of the sh325 shRNA. Upon
hybridization, this "sh3" probe should protect short RNA
expressed in sh321 vector-transduced cells from RNase
digestion. As negative controls, RNA from U6PT-trans-
duced cells was subjected to the RNase protection proce-
dure, and the sh3 probe was treated with RNase without
target RNA. As a positive control a probe for the Mir-16
miRNA was constructed and used to detect endogenous
Mir-16 miRNA in U6PT-transduced cells using the same
protocol (Figure 5C). Sh3 probe-protected RNA was
detected in sh321-transduced cells. Reducing the viral titre
clearly reduced the expression of shRNA and this corre-
Table 1: Construct details and shRNA sequences. Vector names and the shRNA sequences they encode. In comments, numbers are 
coding human PAI-2 mRNA nucleotides (adapted from accession number M18082).
Hairpin sequence
Name sense loop antisense Comments
sh319 GCGCACACCUGUACAGAUG CAAGCUUC CAUCUGUACAGGUGUGCGC PAI-2 684–702
sh321 GCGCACACCUGUACAGAUGAU CAAGCUUC AUCAUCUGUACAGGUGUGCGC PAI-2 684–704
sh323 GCGCACACCUGUACAGAUGAUGU CAAGCUUC ACAUCAUCUGUACAGGUGUGCGC PAI-2 684–706
sh325 GCGCACACCUGUACAGAUGAUGUAC CAAGCUUC GUACAUCAUCUGUACAGGUGUGCGC PAI-2 684–708
sh319scr GUCAUACCGGCAAGGAUCC CAAGCUUC GGAUCCUUGCCGGUAUGAC scrambled sh319
sh325scr GGCCGGAGAUAAGUUCACUCAACUC CAAGCUUC GAGUUGAGUGAACUUAUCUCCGGCC scrambled sh325
sh119 GAAGACCAGAUGGCCAAGG CAAGCUUC CCUUGGCCAUCUGGUCUUC PAI-2 151–169
EGFP No hairpin, empty vector. none
U6PT Human U6 promoter/terminator, no hairpin. noneBMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
Page 7 of 15
(page number not for citation purposes)
Shorter shRNA length reduced, but did not eliminate, cytotoxicity Figure 3
Shorter shRNA length reduced, but did not eliminate, cytotoxicity. A represents flow cytometry analysis of IS-1 cells 
4 and 10 days after transduction with U6PT, sh319, sh321, sh323 and sh325 vectors. GFP expression is detected, and the per-
centage of GFP expressing cells was determined using the M1 gating shown (percentage GFP positive cells is shown in each his-
togram). B shows a comparative analysis of PAI-2 and OAS1 mRNA, in the samples described in A, 4 days after transduction. 
Data were generated by QRT-PCR and error bars are as described in previous figures. In C, cell lysates from samples of trans-
duced cells described in A and B were subjected to immunoblotting with anti-PAI-2 monoclonal antibodies. Ponceau S staining 
served as a gel loading control, as did comparison of a single non-specific band (NS) in the immunoblot. D shows QRT-PCR 
analysis, as in B, for IS-1 cell mRNAs after transduction with or without U6PT, sh319, sh319scr and sh321 vectors.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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PAI-2-targeted RNAi with overexpression of functional PAI-2 in IS-1 cells Figure 4
PAI-2-targeted RNAi with overexpression of functional PAI-2 in IS-1 cells. IS-1 cells were transduced with a lentivi-
ral vector for delivery of the human PAI-2 cDNA under control of the CMV promoter. A shows a flow cytometry analysis for 
detection of PAI-2 in transduced IS-1 PAI-2, and non-transduced IS-1 cells. Both cell types were fixed, permeabilised and 
labelled with anti-PAI-2 monoclonal antibodies, then incubated with PE-labelled secondary antibodies. In B, the functional activ-
ity of overexpressed PAI-2 was assessed by immunoblotting of cell lysates, for PAI-2 expression, with or without the addition 
of 10U of u-PA. u-PA alone is included in lane 1. In C, PAI-2 protein levels were assessed in cell lysates from IS-1 PAI-2 cells, 
after transduction with U6PT, sh319, sh321, sh323 and sh325 vectors. NS in B and C highlights a single non-specific band which 
is consistently detected in PAI-2 immunoblots of IS-1 cell lysates. D represents flow cytometry analysis of IS-1 PAI-2 cells 4 and 
10 days after transduction with U6PT, sh319, sh321, sh323 and sh325 vectors. GFP expression is detected, and the percentage 
of GFP expressing cells was determined using the M1 gating shown (percentage GFP positive cells are given in each histogram). 
E and F show comparative analyses of PAI-2 and OAS1 mRNA expression, respectively, in samples described in D. Samples 
were analysed 4 days after transduction. Data were generated by QRT-PCR, each target gene was detected in duplicate, error 
bars represent the standard deviation of mean values.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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lated with reduced OAS1 induction. Sh3 probe-protected
RNA was not detected in control-transduced cells and the
sh3 probe was completely digested in the absence of target
RNA (Figure 5C). This data demonstrates that vector-
derived shRNA expression can be reduced without
impacting gene silencing and that lower expression corre-
lates with a reduced interferon response.
Loss of long-term gene silencing despite persistent 
transduction marker gene expression
In an attempt to generate a cell line with stable PAI-2
mRNA silencing without interferon response induction,
we generated additional vectors which deliver 19 to 25
nucleotide shRNAs targeting different regions of the PAI-
2 mRNA. Of these, the sh119 construct reduced PAI-2
expression, did not induce OAS1 and had no effect on cell
morphology one week after transduction (data not
shown). In parallel, we transduced IS-1 cells with the
sh119 vector or a GFP control vector. We achieved high
percentage transduction rates which were monitored for
over two weeks (Figure 6A). GFP positive cells, from con-
trol- and sh119-transduced populations were sorted
twice, using flow cytometry, to further enrich the GFP pos-
itive population of each (EGFPs and sh119s). Sh119-
transduced cells showed PAI-2 gene silencing 10 days after
transduction but not after one month of cell culture (Fig-
ure 6B and 6C). GFP marker gene expression was main-
tained in both sorted cell populations. During the
prolonged culture period we noticed that, while the
percentage of GFP positive cells remained stable, the
intensity of GFP detected was reduced in the sh119-trans-
duced cells, compared to GFP alone controls (Figure 6A).
This was accompanied by a significant reduction in inte-
grated vector copies (data not shown). Thus, although the
marker protein was maintained at a reduced expression
level, the prolonged culture period selected against cells
with effective gene silencing. This suggests the presence of
subtle cytotoxic effects of short dsRNA expression which
are not apparent in the initial post transduction period
and are in the absence of interferon response gene induc-
tion. Overexpression of PAI-2 in the IS-1 cells did not
reduce the long-term selective effect on transduced cells or
GFP expression levels in sh119-transduced cells (see Table
3).
Discussion
Here we report the use of lentiviral vectors for the delivery
of expression cassettes designed for RNAi-induced stable
knock-down of gene expression. We undertook this
approach because of the promise of RNAi to easily create
cell lines that are specifically deficient in one protein com-
ponent. By using lentiviral vectors for shRNA expression,
high transduction efficiencies can be achieved, avoiding
effects due to clonal selection of phenotypically different
cells.
We successfully targeted the PAI-2 mRNA with the aim of
studying the effects of reducing PAI-2 activity on cell sen-
sitivity to apoptosis-inducing stimuli. PAI-2 activity has
previously been implicated in protection from apoptosis
[24]. The cytotoxic effect we observed, in cells transduced
with RNAi-inducing vectors, appeared to correlate well
with the reduction in PAI-2 protein levels. However, rapid
selective growth pressure on cells bearing shRNA con-
structs with scrambled sequences, having no complemen-
tarity to the PAI-2 mRNA, suggested non-specific effects
rather than a PAI-2-related phenotype. Using GFP as a
marker gene, delivered by all vectors, enabled very
sensitive detection of selective effects on transduced cells
even when initial cell culture suggested stable transduc-
tion and cell growth.
We were able to detect increased expression of an inter-
feron response gene, OAS1, in cells transduced with all
hairpins of 21 or more base-paired nucleotides. A 21 mer
hairpin induced the most potent OAS1 induction. These
results, and those of others [21,22], suggest that dsRNAs
of less than 30 nucleotides can induce an interferon
response, even if they cannot directly activate protein
kinase R [19]. The absence of OAS1 induction in cells
Table 2: Percentage GFP positive cells over time in shRNA-expressing IS-1 and HeLa cells. Transduced cells were assessed for GFP 
expression by flow cytometry. GFP positive cells were gated equally for each cell type, 4, 8 and 11 days after transduction with EGFP, 
sh319 and sh319scr vectors.
% GFP positive cells
IS-1 HeLa
Vector Day 4 Day 8 Day 11 Day 4 Day 8 Day 11
EGFP 95 95 93 92 94 93
s h 3 1 9 8 67 05 67 96 85 0
sh319scr 90 76 59 82 64 45BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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Efficient target gene silencing with reduced OAS1 induction and lower shRNA expression Figure 5
Efficient target gene silencing with reduced OAS1 induction and lower shRNA expression. Total RNA was iso-
lated from IS-1 cells (CTRL) or IS-1 cells 4 days after transduction with U6PT, sh319 or sh321 vectors. After reverse transcrip-
tion, cDNA was analysed for expression of PAI-2 (A) and OAS1 (B). Data were generated by QRT-PCR, each target gene was 
detected in triplicate, error bars represent the standard deviation of mean values. 1 ml or 0.1 ml of each lentiviral vector stock 
was used, hence the designations 1 and 0.1. Vector titres were approximately 106 transducing units per ml resulting in a multi-
plicity of transduction of approximately 10 for 1 ml used or 1 for 0.1 ml used. In C, shRNA expression was detected in total 
cell RNAs using a modified RNase protection protocol. Total RNA was mixed with radiolabelled probes for hybridization and 
RNase protection. Samples were resolved on a 15 % Acrylamide/8M Urea/TBE gel and RNase protected probes detected by 
autoradiography. Lane 1 shows the Mir-16 probe without RNase digestion or target RNA, lane 2 is as lane 1 with RNase diges-
tion and lane 3 as lane 2 with U6PT-transduced cell RNA as hybridization target. Lane 4 shows the sh3 probe without RNase 
digestion or target RNA, lane 5 as lane 4 with RNase digestion and lane 6 as lane 5 with U6PT-transduced cell RNA as hybrid-
ization target. In lane 7 sh321-transduced cell RNA was used as the hybridization target for the sh3 probe with RNase diges-
tion, and lane 8 is as lane 7 except that cells were transduced with 10-fold less vector titre (sh321 1 and sh321 0.1). Known 
nucleotide lengths (Ntds.) for the probes and the protected Mir-16 endogenous RNA are marked.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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Long-term gene silencing is not stable, despite persistent marker gene expression Figure 6
Long-term gene silencing is not stable, despite persistent marker gene expression. In A, IS-1 cells transduced with 
EGFP control or sh119 vectors were analysed by flow cytometry 3 and 17 days after transduction, and compared to non-trans-
duced cells. EGFP expressing cells, from both transduced cell populations, were selected by cell sorting and named EGFPs and 
sh119s. 39 days after transduction, these cells were analysed for EGFP expression. Percentage EGFP positive cells, assessed by 
the M1 gating shown, are given in each histogram. In B, PAI-2 expression in EGFP and sh119 vector-transduced cell lysates 
were analysed by immunoblotting, 10 days after transduction. C is the same PAI-2 immunoblot as B, performed using EGFPs 
and sh119s cell lysates, 33 days after transduction.BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
Page 12 of 15
(page number not for citation purposes)
transduced with 19 mer shRNAs implies that the search
for appropriate hairpin sequences should be limited to
stretches of this length or less.
Overexpression of functional PAI-2 did not rescue the
cytotoxic effects or OAS1 induction observed in cells
transduced with a series of vectors for expression of differ-
ent length shRNAs. This result, the cytotoxicity associated
with scrambled sequence hairpin-encoding constructs,
and the same selective pressure seen on the growth of
transduced HeLa cells, which do not express detectable
PAI-2 mRNA or protein (Table 2 and data not shown),
lead us to conclude that the phenotype we have seen in IS-
1 cells is not PAI-2-specific. Without the ability to track
transduced cells, via GFP expression, this conclusion
would have been more difficult to obtain. In cells engi-
neered to overexpress functional PAI-2, our RNAi-induc-
ing vectors clearly reduced PAI-2 protein levels but did not
significantly reduce the overexpressed PAI-2 mRNA. This
suggests that in the presence of high concentrations of tar-
geted mRNA, the machinery necessary for RNAi-induced
mRNA cleavage is saturated and mRNA down-regulation
undetectable. As protein levels are nevertheless reduced,
the shRNA may be functioning post-transcriptionally, per-
haps in a similar manner to natural miRNA. This phe-
nomenon has been described elsewhere for siRNAs [27].
IS-1 cell transduction, using one PAI-2 targeting vector
(sh119), initially appeared stable, compared to control-
transduced cells. PAI-2 protein levels were clearly reduced
10 days after transduction and selective pressure on cell
growth appeared to be minimal, as the percentage of
sh119 GFP positive cells was apparently stable at about 80
%, 17 days after transduction. However, after cell sorting
of GFP positive cells and prolonged cell culture of over
one month after transduction, the PAI-2 antigen meas-
ured in sh119s (s for selected) cells was restored to con-
trol-transduced cell levels. Despite maintenance of
transduction marker expression, gene silencing was
absent. The GFP expression levels in selected sh119s cells
was reduced after one month of growth, compared to cells
monitored three days after transduction. It is possible that
we selected cells with a greatly reduced, non-cytotoxic
shRNA expression level, as we have detected a reduced
number of integrated vector copies. The negative selective
effect on cells transduced with the sh119 vector was not
due to the suppression of PAI-2 expression, as PAI-2 over-
expressing cells showed the same negative selection.
In all experiments in which a selective pressure on growth
was apparent on shRNA-expressing cells, reduced percent-
age GFP positive cells and reduced GFP expression in
transduced cells was measured over time. We hypothe-
sised that very high expression levels of the various shR-
NAs is cytotoxic. This could occur via high numbers of
transcriptionally active vector integration events or inte-
gration at transcriptionally active chromosomal regions.
Both might be controlled using a tightly regulatable
expression system, which has been described [15], but
may require careful dosage in a gene- and cell-specific
manner.
Our data demonstrate the importance of appropriate con-
trols for using RNAi, as proposed in a recent editorial [28].
These include suppression of the RNAi phenotype by tar-
get gene overexpression, use of scrambled dsRNAs, and
monitoring of non-specific gene expression in particular
of interferon-responsive genes such as OAS1. Also, if con-
sidering the use of stable RNAi, it is imperative that stable
knock-down is demonstrated as well as stable marker
gene expression. In the cell culture system we used, con-
clusions drawn from experiments several days after RNAi
delivery mask effects which are only apparent days later by
monitoring the percentage of transduced cells. Such
effects are likely be present in experiments using regulata-
ble RNAi systems or using exogenously added dsRNA,
where the experimental data linked to gene targeting may
be collected before other effects are seen. The molecular
events which lead to the long-term effect we have docu-
mented may well be underway during this experimental
period.
In the light of our own data and other recent reports [20-
22], solutions for the induced cytotoxic effects we describe
Table 3: Percentage GFP positive cells and mean GFP fluorescence in sh119-transduced IS-1 and IS-1 PAI-2 cells. Transduced cells were 
assessed for GFP expression by flow cytometry. GFP positive cells were gated equally for each cell type, 5 and 31 days after transduction 
with the sh119 vector. Mean F is the mean fluorescence of gated GFP positive cells.
% GFP positive cells Mean F of GFP positive cells
Day5 Day31 Day5 Day31
IS-1 cells 85 40 146 83
IS-1 PAI-2 cells 82 46 180 96BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
Page 13 of 15
(page number not for citation purposes)
here include testing a series of target sequences, using
dsRNA of no more than 19 nucleotides at low effective
vector doses, and careful monitoring of transduced cell
phenotype with and without functional target gene
overexpression. Long-term monitoring of gene silencing
appears to be necessary in stable systems, even in the pres-
ence of marker gene expression.
Conclusions
Our study demonstrates vector-derived RNAi in tumor cell
lines and points towards the necessity of careful, but
clearly feasible, controls when using RNAi for stable gene
suppression in short- and long-term experiments.
Methods
Cell lines
Isreco-1 (IS-1) cells were a gift from Dr. B. Sordat (ISREC,
Lausanne). 293T cells were a gift from Dr. D. Trono
(Geneva University Medical Centre). HeLa cells were pur-
chased from the European collection of cell cultures,
ECACC number: 93021013. All cells were maintained in
DMEM supplemented with 10 % Fetal Bovine Serum and
10 mM HEPES pH 7.4 (IS-1 medium) (purchased from
Invitrogen).
Plasmid constructions
Gene transfer plasmids, for RNA interference using lenti-
viral vectors, were constructed using the backbone of
ploxEWiresGFP, a gift from Dr. P. Salmon, Geneva Uni-
versity Medical Centre. The human U6 gene was amplified
by PCR using HeLa cell genomic DNA as template and the
oligonucleotides U6-ClaI-F 5' GATC ATCGATAAGGTCG-
GGCAGGAAGAGGGCCTATTTCCC 3' and U6-ClaI-R 5'
GATCATCGATTGGTAAACCGTGCACCGGCGATAAACG
3'. The 483 base pair PCR product was digested with ClaI,
inserted into the ClaI site of pTRE2 hyg (Clontech), and its
sequence verified by DNA sequencing. The U6 promoter
and gene sequence corresponded to nucleotides 65 to 527
of Genbank accession number M14486. This plasmid was
used as template for PCR reactions to amplify U6
promoter-driven expression cassettes. Each PCR product
included the U6 promoter with shRNA-encoding
sequences beginning at the U6 +1 site, and a run of 6 or 7
thymidine bases for an RNA polymerase III transcription
termination signal. Each PCR introduced flanking ClaI
restriction sites. PCR products were directly cloned into
the pGEM Teasy (Promega) plasmid and sequenced. ClaI
fragments of positive clones were excised and ligated into
the unique ClaI site of ploxEWiresGFP. The U6 promoter
cassettes in the resulting lentiviral vector plasmids were
verified by DNA sequencing. Each construct used for vec-
tor production had the same orientation of the U6 expres-
sion cassette with respect to the PEF-1α-iresGFP region of
the plasmid. A schematic of the gene transfer cassette is
given in Figure 1A. Details of shRNA sequences used for
each construct are given in Table 1. The gene transfer plas-
mid for PAI-2 overexpression was constructed by replac-
ing the EGFP gene from ploxCW-GFP (a gift from Dr. P.
Salmon, Geneva University Medical Centre) with the type
B human PAI-2 (SERPINB2) [29] open reading frame.
Vector production and transduction
Lentiviral vectors were produced by three plasmid co-
transfection of 293T cells, essentially as described previ-
ously [30]. Vectors were harvested 48 hours after transfec-
tion, passed through 0.45 µm filters and used directly on
target cells in a 1:1 ratio with IS-1 medium in a total vol-
ume of 2 ml. Transductions were performed in 3 cm diam-
eter 6-well plates, on cells seeded the previous day at 5 ×
104 or 1 × 105 cells/well. Upon addition of vectors, plates
were centrifuged for one hour at 1000 g in the presence of
8  µg/ml polybrene (hexadimethrine bromide, Sigma).
After 24 hours, target cells were washed twice with PBS
and cultured in IS-1 medium until analysis. Where indi-
cated, viral titre was determined by transducing cells with
10 µl of lentiviral vector conditioned medium from 293T
cell producer cells and measuring the % of GFP positive
cells by flow cytometry. We routinely achieve 106 effective
transducing units per ml of producer cell conditioned
medium, which results in a typical multiplicity of trans-
duction of 10. Comparisons between cell populations
transduced with different vectors is made by flow cytome-
try analysis of GFP positive cells.
Antibodies
Anti-human PAI-2 monoclonal antibody 3750 was pur-
chased from American Diagnostica. PE-labelled goat anti-
mouse antibodies were purchased from Pharmingen.
HRP-conjugated goat anti-mouse antibodies were pur-
chased from Bio-Rad.
Flow cytometry
Flow cytometry was performed using Becton Dickinson
FACScan, FACStrack or FACScalibur instruments at the
Geneva University Medical Centre flow cytometry facility.
GFP was detected in cells detached and resuspended in
FACS buffer comprising 1 % BSA in PBS supplemented
with 0.05 % sodium azide. For the detection of
intracellular PAI-2, a method adopted from Dr. M. Ran-
son (University of Wollongong, Australia) was used. Cells
were detached and fixed in 0.25 % paraformaldehyde
(PAF)/PBS for one hour on ice. Cells were permeabilised
in 0.1 % saponin/PBS for 30 minutes at room tempera-
ture. Fixed, permeabilised cells were incubated for 30
minutes in PBS/0.5 % BSA/0.1 % saponin containing 2
µg/ml 3750 anti-PAI-2 monoclonal antibody, washed
twice in PBS/0.1 % saponin and incubated for 30 minutes
in 0.1 % saponin/0.5 % BSA/PBS/goat anti-mouse-PE
antibodies. Finally, cells were washed twice in 0.1%BMC Molecular Biology 2004, 5:9 http://www.biomedcentral.com/1471-2199/5/9
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saponin/PBS, twice in PBS and resuspended in 2.5 % PAF
for flow cytometric analysis.
Sorting of live GFP positive cells was performed using a
FACStar+ instrument (Becton Dickinson).
Western blotting of cell lysates
Cells in suspension were lysed in 10 mM Tris-HCl (pH
7.4), 10 mM NaCl, 0.5 % NP-40, 3 mM MgCl2, 5 mM DTT
and 1 mM PMSF for one hour on ice. Lysates were centri-
fuged at 16000 g for 5–10 minutes to remove nuclei and
precipitates. Supernatant protein concentrations were
measured using the Bio-Rad protein assay with BSA in
lysis buffer as a standard. Cell lysates were separated by
reducing SDS-PAGE and transferred to nitrocellulose
membranes. Equal total protein lysate was used for each
blot, between 2.5 and 10 µg depending on the assay.
Membranes were blocked for 1 hour at room temperature
in TBS-0.1 % Tween 20/5 % non-fat milk, and probed
using antibodies in TBS-0.1 % Tween 20/5 % non-fat
milk. The 3750 anti-PAI-2 antibody was used at a concen-
tration of 1 µg/ml.
Microscopy
Phase contrast microscopy was performed using a Zeiss
Axiovert 100 M instrument on live cells. Images were col-
lected using a Hamamatsu CCD camera (ORCA-100).
PAI-2 functional activity
To measure PAI-2 functional activity, IS-1 and IS-1 PAI-2
cells were lysed in 1 % NP-40, 150 mM NaCl and 50 mM
Tris pH 8.0. Thereafter, 6 µg of cleared total cell lysate was
incubated with and without 10 U of low molecular weight
urokinase (u-PA). 3 µg total cell lysate samples were then
subjected to reducing SDS-PAGE and immunoblotting as
for other PAI-2 immunoblots.
Quantitative RT-PCR analysis of mRNA
Total RNA was isolated from cells using RNA preparation
kits from Qiagen or TRIZOL® reagent (Invitrogen). cDNA
was generated using ImpromII®  reverse transcriptase
(Promega) and random hexamers, according to the man-
ufacturers instructions, typically using 1 µg of total RNA
per reaction. Quantitative PCR was performed using an
Applied Biosystems Prism 7000 instrument using Applied
Biosystems SYBR® green master mix reagent and oligonu-
cleotide pairs to detect hypoxanthine phosphoribosyl
transferase (HPRT), PAI-2 and oligoadenylate synthase-1
(OAS1) cDNA. 5' to 3' primer sequences were as follows:
HPRT forward TATTGTAATGACCAGTCAACAG, HPRT
reverse GGTCCTTTTCACCA GCAAG, PAI-2 forward
GGGTCAAGACTCAAACCAAAG, PAI-2 reverse CCTTT-
GAAGTAGACAGCATTC, OAS1 forward AGGTGG-
TAAAGGGT GGCTCC and OAS1 reverse
ACAACCAGGTCAGCGTCAGAT. Data were analysed
using Applied Biosystems Prism software and the ∆CT
method. Briefly, target gene expression was normalised to
the HPRT endogenous reference gene for each sample.
The difference between mean threshold PCR cycle values
for target and control genes gave the ∆CT value. This was
then calibrated to the control sample in each experiment
to give the ∆∆CT value, where the control had a ∆∆CT value
of 0. The fold target gene expression, compared to the cal-
ibrator value, is given by the formula 2-∆∆CT. Error bars
represent the standard deviation of each target gene value,
after evaluating the expression 2-∆∆CT+s and 2-∆∆CT-s, where
s is the standard deviation of the ∆∆CT value. All reactions
were performed in duplicates or triplicates.
ShRNA detection
Expression of shRNAs was detected using the mirVana™
Probe Construction and miRNA Detection kits from
Ambion (Austin), according to the manufacturers
instructions. These kits employ in vitro transcription for
radiolabelled probe generation and an RNase protection
protocol for detection of small RNA expression, respec-
tively. Briefly, radiolabelled RNA probes incorporating α-
32P-UTP (Amersham) were constructed using T7 polymer-
ase-driven transcription templates. Templates were
designed to generate RNAs which hybridize to the endog-
enous Mir-16 miRNA, as a control, or the first 19 nucle-
otides of the sh325 shRNA (see table 1). The sh3 probe
should therefore hybridize to any of the sh319/sh321/
sh323 or sh325-derived shRNAs. Before hybridization,
radiolabelled probes were purified by migration of the
transcription reaction on a 12 or 15% Acrylamide/8 M
Urea denaturing gel and elution of radioactive probe
bands after detection by autoradiography. 3 µg of total
cellular RNA was used for all hybridizations and RNase
protections, supplemented with 2 µg yeast RNA as a car-
rier. Control reactions without target RNA but with or
without RNase digestion included 5 µg yeast RNA. After
hybridization and RNase digestion, protected probes were
detected by autoradiography after migration in a 15% acr-
ylamide/8 M Urea denaturing gel.
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